Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Recommendation of “Hold” by Analysts

Keros Therapeutics, Inc. (NASDAQ:KROS) has been assigned an average rating of “Hold” from the fourteen ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $30.1111.

Several equities analysts have recently issued reports on the stock. Wedbush lifted their price objective on shares of Keros Therapeutics from $15.00 to $16.00 and gave the stock a “neutral” rating in a research note on Thursday. HC Wainwright decreased their price target on shares of Keros Therapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Wells Fargo & Company initiated coverage on Keros Therapeutics in a report on Monday, October 20th. They issued an “overweight” rating and a $26.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Keros Therapeutics in a research note on Wednesday, October 8th.

Keros Therapeutics Stock Up 0.2%

Shares of KROS stock opened at $16.20 on Friday. The stock has a 50-day simple moving average of $15.50 and a 200 day simple moving average of $14.63. The stock has a market capitalization of $493.61 million, a P/E ratio of 10.52, a P/E/G ratio of 2.08 and a beta of 1.12. Keros Therapeutics has a fifty-two week low of $9.12 and a fifty-two week high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($1.11) by $0.93. Keros Therapeutics had a net margin of 26.12% and a return on equity of 9.63%. The firm had revenue of $14.26 million for the quarter, compared to analysts’ expectations of $4.22 million. During the same period in the previous year, the business earned ($1.41) earnings per share. Keros Therapeutics’s revenue for the quarter was up 3585.6% compared to the same quarter last year. On average, sell-side analysts anticipate that Keros Therapeutics will post -4.74 earnings per share for the current year.

Insider Transactions at Keros Therapeutics

In other news, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of Keros Therapeutics stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total value of $84,975,125.25. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of Keros Therapeutics stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total transaction of $95,659,436.00. The disclosure for this sale is available in the SEC filing. Company insiders own 20.60% of the company’s stock.

Hedge Funds Weigh In On Keros Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CWM LLC boosted its position in Keros Therapeutics by 10,157.7% during the first quarter. CWM LLC now owns 2,667 shares of the company’s stock valued at $27,000 after purchasing an additional 2,641 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Keros Therapeutics by 149.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after buying an additional 1,888 shares during the last quarter. Farther Finance Advisors LLC bought a new stake in shares of Keros Therapeutics in the 3rd quarter valued at approximately $47,000. SG Americas Securities LLC acquired a new position in Keros Therapeutics in the third quarter worth approximately $103,000. Finally, Police & Firemen s Retirement System of New Jersey raised its position in Keros Therapeutics by 29.7% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 8,257 shares of the company’s stock valued at $110,000 after acquiring an additional 1,892 shares in the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.